Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans

Overview

Journal Obes Surg

Date 2018 Sep 24

PMID 30244333

Citations 23

Authors

Shahar Azar

Shiri Sherf-Dagan

Alina Nemirovski

Muriel Webb

Asnat Raziel

Andrei Keidar

David Goitein

Nasser Sakran

Oren Shibolet

Joseph Tam

Shira Zelber-Sagi

Affiliations

Soon will be listed here.

Abstract

Background: The endocannabinoid (eCB) system plays a key role in the development of obesity and its comorbidities. Limited information exists on the changes in circulating eCBs following bariatric surgery.

Objectives: This study aims to (i) assess the circulating levels of eCBs and related molecules and (ii) examine the association between their levels and numerous clinical/metabolic features pre- and post-operatively.

Methods: Sixty-five morbidly obese patients (age 42.78 ± 9.27 years; BMI 42.00 ± 5.01 kg/m) underwent laparoscopic sleeve gastrectomy (LSG) surgery, and were followed up for 12 months. Data collected included anthropometrics and metabolic parameters. The serum levels of the eCBs, 2-arachidonoylglycerol (2-AG), anandamide (AEA); and their related molecules, arachidonic acid (AA) and oleoylethanolamine (OEA) were measured by liquid chromatography-mass spectrometry.

Results: Levels of 2-AG, AEA, and AA were reduced post operatively with no differences in serum OEA levels. The delta changes in eCB levels between pre- and post-operation were correlated with the delta of different metabolic parameters. Positive correlations were found between delta AA and waist circumference (WC) (r = 0.28, P < 0.05), free fat mass (r = 0.26, P < 0.05), SteatoTest score (r = 0.45, P < 0.05), and ALT (r = 0.32, P < 0.05). Delta AEA levels positively correlated with WC (r = 0.30, P < 0.05). Delta 2-AG levels positively correlated with total cholesterol (r = 0.27, P < 0.05), triglycerides (r = 0.55, P < 0.05), and SteatoTest score (r = 0.27, P < 0.05). Delta OEA levels negatively correlated with fasting glucose levels (r = - 0.27, P < 0.05).

Conclusions: This study provides compelling evidence that LSG surgery induces reductions in the circulating 2-AG, AEA, and AA levels, and that these changes are associated with clinical benefits related to the surgery including reduced fat mass, hepatic steatosis, glucose, and improved lipid profile.

Citing Articles

Higher plasma levels of endocannabinoids and analogues are correlated with a worse cardiometabolic profile in middle-aged adults.

Rodriguez-Garcia C, Osuna-Prieto F, Kohler I, Sanchez-Gomez J, Ruiz-Campos S, Castillo M J Physiol Biochem. 2024; .

PMID: 39636365 DOI: 10.1007/s13105-024-01063-6.

The circulating and central endocannabinoid system in obesity and weight loss.

Mattelaer N, Van der Schueren B, Van Oudenhove L, Weltens N, Vangoitsenhoven R Int J Obes (Lond). 2024; 48(10):1363-1382.

PMID: 38834796 DOI: 10.1038/s41366-024-01553-z.

Influence of Bariatric Surgery on Gut Microbiota Composition and Its Implication on Brain and Peripheral Targets.

Hamamah S, Hajnal A, Covasa M Nutrients. 2024; 16(7).

PMID: 38613104 PMC: 11013759. DOI: 10.3390/nu16071071.

Renal Endocannabinoid Dysregulation in Obesity-Induced Chronic Kidney Disease in Humans.

Permyakova A, Rothner A, Knapp S, Nemirovski A, Ben-Zvi D, Tam J Int J Mol Sci. 2023; 24(17).

PMID: 37686443 PMC: 10487429. DOI: 10.3390/ijms241713636.

Hypoabsorptive surgeries cause limb-dependent changes in the gut endocannabinoidome and microbiome in association with beneficial metabolic effects.

Mukorako P, St-Pierre D, Flamand N, Biertho L, Lebel S, Lemoine N Int J Obes (Lond). 2023; 47(7):630-641.

PMID: 37142736 DOI: 10.1038/s41366-023-01307-3.

References

Mallipedhi A, Prior S, Dunseath G, Bracken R, Barry J, Caplin S . Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasis. J Diabetes Res. 2015; 2015:680867. PMC: 4385619. DOI: 10.1155/2015/680867. View

Westerbacka J, Kotronen A, Fielding B, Wahren J, Hodson L, Perttila J . Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology. 2010; 139(6):1961-1971.e1. DOI: 10.1053/j.gastro.2010.06.064. View

Quarta C, Bellocchio L, Mancini G, Mazza R, Cervino C, Braulke L . CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab. 2010; 11(4):273-85. DOI: 10.1016/j.cmet.2010.02.015. View

Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong W . Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008; 118(9):3160-9. PMC: 2491458. DOI: 10.1172/JCI34827. View

Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G . Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One. 2012; 7(7):e42399. PMC: 3409167. DOI: 10.1371/journal.pone.0042399. View

Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault B, Cartier A . Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia. 2008; 52(2):213-7. DOI: 10.1007/s00125-008-1178-6. View

Kumbhari V, Hill C, Sullivan S . Bariatric endoscopy: state-of-the-art. Curr Opin Gastroenterol. 2017; 33(5):358-365. DOI: 10.1097/MOG.0000000000000383. View

Montecucco F, Lenglet S, Quercioli A, Burger F, Thomas A, Lauer E . Gastric bypass in morbid obese patients is associated with reduction in adipose tissue inflammation via N-oleoylethanolamide (OEA)-mediated pathways. Thromb Haemost. 2014; 113(4):838-50. DOI: 10.1160/TH14-06-0506. View

Zelber-Sagi S, Azar S, Nemirovski A, Webb M, Halpern Z, Shibolet O . Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. Obesity (Silver Spring). 2016; 25(1):94-101. DOI: 10.1002/oby.21687. View

10.

Abdulnour J, Yasari S, Rabasa-Lhoret R, Faraj M, Petrosino S, Piscitelli F . Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. Obesity (Silver Spring). 2013; 22(1):211-6. DOI: 10.1002/oby.20498. View

11.

Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres J . Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond). 2007; 31(4):692-9. DOI: 10.1038/sj.ijo.0803539. View

12.

Gregg E, Shaw J . Global Health Effects of Overweight and Obesity. N Engl J Med. 2017; 377(1):80-81. DOI: 10.1056/NEJMe1706095. View

13.

Poynard T, Munteanu M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O . Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Eur J Gastroenterol Hepatol. 2018; 30(5):569-577. DOI: 10.1097/MEG.0000000000001064. View

14.

Bensaid M, Gary-Bobo M, Esclangon A, Maffrand J, Le Fur G, Oury-Donat F . The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003; 63(4):908-14. DOI: 10.1124/mol.63.4.908. View

15.

Sherf-Dagan S, Zelber-Sagi S, Zilberman-Schapira G, Webb M, Buch A, Keidar A . Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial. Int J Obes (Lond). 2017; 42(2):147-155. DOI: 10.1038/ijo.2017.210. View

16.

Udi S, Hinden L, Earley B, Drori A, Reuveni N, Hadar R . Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD. J Am Soc Nephrol. 2017; 28(12):3518-3532. PMC: 5698062. DOI: 10.1681/ASN.2016101085. View

17.

Guijarro A, Osei-Hyiaman D, Harvey-White J, Kunos G, Suzuki S, Nadtochiy S . Sustained weight loss after Roux-en-Y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function. Ann Surg. 2008; 247(5):779-90. PMC: 2671862. DOI: 10.1097/SLA.0b013e318166fd5f. View

18.

Hillard C . Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?. Neuropsychopharmacology. 2017; 43(1):155-172. PMC: 5719092. DOI: 10.1038/npp.2017.130. View

19.

Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P . CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes. 2010; 59(4):926-34. PMC: 2844840. DOI: 10.2337/db09-1482. View

20.

Tam J, Hinden L, Drori A, Udi S, Azar S, Baraghithy S . The therapeutic potential of targeting the peripheral endocannabinoid/CB receptor system. Eur J Intern Med. 2018; 49:23-29. DOI: 10.1016/j.ejim.2018.01.009. View